17 February 2005 | Updated 04 November 2011 /Prices and reimbursement
The consumption of the antipsychotic medicinal product Zyprexa® decreased during 2004. The decrease in consumption has taken place following EMEA's announcement in March 2004 about a heightened risk of death and brain haemorrhage from treating elderly dementia patients with Zyprexa®.
15 April 2011 | Updated 05 July 2011 /Prices and reimbursement
We monitor the trends in consumption of cardiovascular medicines (blood pressure medicines) in connection with the reimbursement changes for cardiovascular medicines of 13 July 2009 and 15 November 2010.
14 June 2011 /Prices and reimbursement
In 2010, we reached decisions in a total of 144,324 individual reimbursement applications against 138,714 in 2009, corresponding to an increase of 4 %. The figure breaks down to approx. 96,000 applications for single reimbursement (about 3 % fewer than in 2009), approx. 34,000 applications for reimbursement for the chronically ill (about 30 % more than in 2009), approx. 12,000 applications for reimbursement for the terminally ill (about 7 % more than in 2009) and approx. 2,800 applications for increased reimbursement (about 14 % more than in 2009).
23 March 2011 /Prices and reimbursement
In 2010, the Reimbursement Committee reviewed 20 applications for general reimbursement and 1719 applications for individual reimbursement.
06 January 2011 /Prices and reimbursement
Elderly people's consumption of medicinal products is increasing. Regarding all medicine consumers over the age of 64, the sale measured in DKK and defined daily doses has generally increased from 1999 to 2001.